News Wire

The Corrona Psoriasis Registry has announced that it will track drug-safety reporting for ixekizumab (Taltz, Eli Lilly and Company), a new biologic medication recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation and Corrona, LLC, the leading sponsor of registries in autoimmune disease.

Military veterans are more likely to report delays in seeking necessary health care compared with the U.S. general population, according to a study in the Journal of Public Health Management and Practice.

As the costs of emergency surgery soar, new research published in JAMA Surgery has found that just seven procedures account for 80% of admissions, inpatient costs, complications, and deaths. In a separate commentary, Martin G.

Quest Diagnostics has received an emergency use authorization (EUA) from the FDA for the Zika Virus RNA Qualitative Real-Time RT-PCR (Zika RT-PCR) test. The proprietary molecular test is intended for the qualitative detection of RNA from the Zika virus in human serum specimens from certain individuals.

As U.S. lawmakers search for ways to stop the current epidemic of heroin and painkiller abuse, two pharma companies––Titan Pharmaceuticals of San Francisco and Braeburn Pharmaceuticals of Princeton, New Jersey––have joined forces to develop a matchstick-sized implant that market analysts expect will be approved in May, according to a Reuters report.

Positive results have been reported from an international, phase 3, randomized, double-blind, placebo-controlled study evaluating once-weekly ixazomib capsules (Ninlaro, Takeda Pharmaceutical Company) plus lenalidomide and dexamethasone compared with placebo plus lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Researchers at the Icahn School of Medicine at Mount Sinai say that tiny doses of a cancer drug may stop the uncontrollable immune response to infection that leads to sepsis and kills up to 500,000 people a year in the U.S. The new drug treatment may also benefit millions of people worldwide who are affected by infections and pandemics.

Positive results have been reported from the phase 3 clinical trial program for SUN-101 (glycopyrrolate), a nebulized long-acting muscarinic antagonist (LAMA), delivered via the investigational eFlow nebulizer system (SUN-101/eFlow, Sunovion Pharmaceuticals), for patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The Centers for Medicare and Medicaid Services (CMS) wants to replace the meaningful use program for physicians with a program that is “simpler, less burdensome, and more flexible,” according to an article posted on the HealthLeaders Media website.

The FDA has accepted the resubmission of a new drug application (NDA) for Rayaldee (extended-release calcifediol, Opko Health) for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage-3 or -4 chronic kidney disease (CKD) and vitamin D insufficiency.

The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) have released a new clinical practice guideline for non–muscle-invasive bladder cancer (NMIBC). The new document outlines guidance on a variety of topics, including diagnosis and treatment, as well as a risk-stratified clinical framework for postsurgical management of the disease.

Positive results have been reported from the sixth and last global phase 3a study (SUSTAIN 6) of semaglutide (Novo Nordisk), an investigational glucagon-like peptide-1 (GLP-1) analogue, which was administered subcutaneously once weekly in the SUSTAIN trials.

The Department of Health and Human Services (HHS) has issued a final rule on managed care in Medicaid and the Children’s Health Insurance Program (CHIP). The rule is the first overhaul of Medicaid and CHIP managed-care regulations in more than a decade.

The Campaign for Sustainable Rx Pricing, a coalition of hospitals, insurers, and businesses, has released a policy proposal that aims to increase drug-pricing transparency and promote competition. The coalition includes the Federation of American Hospitals, the American Hospital Association, the Blue Cross Blue Shield Association, Kaiser Permanente, and the AARP.

Xtampza ER (oxycodone) extended-release (ER) capsules CII (Collegium Pharmaceutical, Inc.) has won full marketing approval from the FDA. The drug was awarded tentative approval in November 2015, but full approval was contingent on the outcome of a lawsuit filed by Purdue Pharma against Collegium.